Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan European Growth & Income sees improving investor sentiment after H1 outperformance

(Sharecast News) - London-listed investment trust JPMorgan European Growth & Income said it was the best-performing investment trust in its sector over the six months to 30 September, with its portfolio outperforming wider benchmarks by 3.5 percentage points. The trust, which holds cross-industry equity investments across Continental Europe - the biggest being ASML, Novartis and Siemens - reported a total return on net asset value per share of 14.2% over the fiscal first half, compared with benchmark returns of 10.7%.

The benchmark outperformance now stands at 13.2pp over the past there years and 33.4pp over the past five.

The dividend for the first half was 2.4p per share, with the board maintaining its target to pay out 4% of the previous year-end NAV.

Looking ahead, despite a volatile geopolitical outlook for the region, the firm said that valuations of European companies still remain attractive, "particularly relative to their US counterparts", while investment flows into European markets "have started to pick up".

The company did highlight the uncertainty caused by US trade tariffs, as well as the significant capex boom in AI software and infrastructure - amid recent wider market concerns about stretched valuations in the semiconductor and AI-related sectors.

"However, there are tentative signs economic growth in the Eurozone will improve with plenty of self-help and we are seeing positive investor sentiment towards European equity markets," chair Rita Dhut said in an outlook statement.

As of 31 October, nearly half of the trust's portfolio was invested in just four sectors: capital goods (16.7%), banks (12.1%), pharma, biotech and life sciences (11.4%) and insurance (7.4%). In contrast, the chip sector accounted for just 5.0% of the portfolio, while software and services made up just 3.2% of all investments.

The stock was down 0.7% at 134p by 1436 GMT.

Share this article

Related Sharecast Articles

Rightmove facing £1.5bn legal action, shares tumble
(Sharecast News) - Rightmove shares tumbled on Wednesday as it said it would defend itself "vigorously" following reports that a £1.5bn legal claim has been filed against the company with the Competition Appeal Tribunal.
PE firm Arcline not planning to bid for Senior
(Sharecast News) - Private equity firm Arcline Investment Management said on Wednesday that it does not intend to make an offer for engineer Senior.
JPMorgan American Investment Trust reports positive but lagging performance
(Sharecast News) - JPMorgan American Investment Trust reported a positive but lagging performance in 2025 on Wednesday, as its quality-focused investment approach underperformed a market driven by higher-risk stocks, while the board struck an optimistic tone on the outlook for US equities.
Topps Tiles to shut 23 stores in cost-saving bid
(Sharecast News) - Topps Tiles announced plans to shut 23 underperforming stores on Wednesday as the tile specialist looks to save costs.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.